C3.ai Inc vs Merck & Co., Inc. — how do they compare? C3.ai Inc trades at $10.55 (market cap $1.65B), while Merck & Co., Inc. trades at $130.24 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 195× C3.ai Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while C3.ai Inc pays none. Which is the better fit depends on your goals.
| AI | MRK | |
|---|---|---|
Market Cap | $1.65B | $321.77B |
Sector | Technology | Health |
52-Week High | $19.66 | $131.84 |
52-Week Low | $7.76 | $77.60 |
Enterprise Value | $1.08B | $368.53B |
Dividend Yield | — | 2.61% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Trailing returns across standard periods
Latest headlines on both assets
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type
Read more on AI →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →